• GenFleet launched a three-arm Phase II trial in China for GFH375 in pretreated KRAS G12D-mutant advanced pancreatic cancer.
• Study tests two first-in-world combinations versus GFH375 alone, targeting tumor control alongside better tolerability in patients with cachexia.
• GFS202A early clinical results were already presented at the 2026 ASCO meeting, showing encouraging activity with appetite and weight improvements.
• GFH375 previously won China Breakthrough Therapy Designation in February 2026, strengthening its regulatory profile ahead of later-stage development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics (Shanghai) Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260820-12291331), on August 20, 2026, and is solely responsible for the information contained therein.